VRT106

Guangzhou Virotech Pharmaceutical Co., Ltd. · Phase 2 active Biologic

VRT106 is an oncolytic virus being developed by Guangzhou Virotech Pharmaceutical for various solid tumors, including glioblastoma, pancreatic cancer, and gastric cancer. Currently in Phase 1 and 2 trials, it shows promise in combination with chemotherapy and as a standalone treatment. No FDA label yet, but multiple trials are recruiting.

At a glance

Generic name	VRT106
Sponsor	Guangzhou Virotech Pharmaceutical Co., Ltd.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VRT106 CI brief — competitive landscape report
VRT106 updates RSS · CI watch RSS
Guangzhou Virotech Pharmaceutical Co., Ltd. portfolio CI